{
  "success": true,
  "pagesUsed": [
    7,
    8,
    9,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-pro-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_pri_1",
        "name": "Primary Objective 1",
        "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
        "level": {
          "code": "Primary",
          "codeSystem": "USDM",
          "decode": "Primary"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_1",
        "name": "Secondary Objective 1",
        "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_2",
        "name": "Secondary Objective 2",
        "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_3",
        "name": "Secondary Objective 3",
        "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_4",
        "name": "Secondary Objective 4",
        "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_5",
        "name": "Secondary Objective 5",
        "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_6",
        "name": "Secondary Objective 6",
        "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_sec_7",
        "name": "Secondary Objective 7",
        "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_exp_1",
        "name": "Exploratory Objective 1",
        "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_exp_2",
        "name": "Exploratory Objective 2",
        "text": "Determine the effect of treatment duration on copper balance in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_exp_3",
        "name": "Exploratory Objective 3",
        "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint 1",
        "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Primary",
          "codeSystem": "USDM",
          "decode": "Primary"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy",
        "objectiveId": "obj_pri_1"
      },
      {
        "id": "ep_2",
        "name": "Secondary Endpoint 2",
        "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy",
        "objectiveId": "obj_sec_1"
      },
      {
        "id": "ep_3",
        "name": "Secondary Endpoint 3",
        "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic",
        "objectiveId": "obj_sec_2"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint 4",
        "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic",
        "objectiveId": "obj_sec_3"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint 5",
        "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic",
        "objectiveId": "obj_sec_4"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint 6",
        "text": "Accumulation of molybdenum as determined by molybdenum balance",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic",
        "objectiveId": "obj_sec_5"
      },
      {
        "id": "ep_7",
        "name": "Secondary Endpoint 7",
        "text": "PK parameters for plasma total and PUF-molybdenum",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic",
        "objectiveId": "obj_sec_6"
      },
      {
        "id": "ep_8",
        "name": "Secondary Endpoint 8",
        "text": "Safety parameters: • Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs) • Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis) • Physical examinations • Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG • Vital sign assessments (blood pressure and heart rate)",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety",
        "objectiveId": "obj_sec_7"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Endpoint 9",
        "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy",
        "objectiveId": "obj_exp_1"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Endpoint 10",
        "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy",
        "objectiveId": "obj_exp_2"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Endpoint 11",
        "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
        "level": {
          "code": "Exploratory",
          "codeSystem": "USDM",
          "decode": "Exploratory"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker",
        "objectiveId": "obj_exp_3"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 7,
      "exploratoryObjectives": 3,
      "totalEndpoints": 11,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "primaryObjectives": [
      {
        "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
        "endpoints": [
          {
            "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
            "purpose": "Efficacy"
          }
        ]
      }
    ],
    "secondaryObjectives": [
      {
        "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
        "endpoints": [
          {
            "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
            "purpose": "Efficacy"
          }
        ]
      },
      {
        "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
        "endpoints": [
          {
            "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
            "purpose": "Pharmacokinetic"
          }
        ]
      },
      {
        "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
        "endpoints": [
          {
            "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
            "purpose": "Pharmacokinetic"
          }
        ]
      },
      {
        "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "endpoints": [
          {
            "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
            "purpose": "Pharmacokinetic"
          }
        ]
      },
      {
        "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
        "endpoints": [
          {
            "text": "Accumulation of molybdenum as determined by molybdenum balance",
            "purpose": "Pharmacokinetic"
          }
        ]
      },
      {
        "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
        "endpoints": [
          {
            "text": "PK parameters for plasma total and PUF-molybdenum",
            "purpose": "Pharmacokinetic"
          }
        ]
      },
      {
        "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "endpoints": [
          {
            "text": "Safety parameters: • Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs) • Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis) • Physical examinations • Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG • Vital sign assessments (blood pressure and heart rate)",
            "purpose": "Safety"
          }
        ]
      }
    ],
    "exploratoryObjectives": [
      {
        "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
        "endpoints": [
          {
            "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
            "purpose": "Efficacy"
          }
        ]
      },
      {
        "text": "Determine the effect of treatment duration on copper balance in participants with WD",
        "endpoints": [
          {
            "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
            "purpose": "Efficacy"
          }
        ]
      },
      {
        "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
        "endpoints": [
          {
            "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
            "purpose": "Biomarker"
          }
        ]
      }
    ],
    "estimands": []
  }
}